Terms: = Thyroid cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Staging
6 results:
1. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
2. BRAF
Bakkar S; Macerola E; Aljarrah Q; Proietti A; Materazzi G; Basolo F; Miccoli P
Updates Surg; 2019 Dec; 71(4):701-704. PubMed ID: 31586312
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
4. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract] [Full Text] [Related]
5. Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma.
Pinto AE; Silva G; Banito A; Leite V; Soares J
Oncol Rep; 2008 Oct; 20(4):913-9. PubMed ID: 18813835
[TBL] [Abstract] [Full Text] [Related]
6. thyroid carcinoma.
Gillenwater AM; Weber RS
Cancer Treat Res; 1997; 90():149-69. PubMed ID: 9367082
[TBL] [Abstract] [Full Text] [Related]
